L

Lupin Pharmaceuticals

Global pharmaceutical manufacturer and distributor

Human Resources Specialist

Full-TimeDeadline 3/6/27
No salary listed
Mid
Bachelor's
Coral Springs, FL, USA
In PersonWork is performed on site in an office environment.
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A bachelor's degree in Human Resources or a related field is required.
  • Two to five years of experience relevant to the listed responsibilities is required.
  • Demonstrated problem-solving, teamwork, communication, collaboration, and analytical skills are required.
  • Experience handling sensitive and confidential information is required.
  • Problem-solving skills and resourceful thinking are required.
  • Strong empathy and interpersonal skills are required.
  • Working knowledge of Microsoft Excel, Microsoft Word, Microsoft PowerPoint, and other human resources information management systems is required.
  • Exceptional attention to detail and organizational skills are required.
  • The position requires the ability to perform office-based physical activities, including standing, walking, sitting, using hands and fingers, reaching, talking, and hearing; occasional lifting of up to 15 pounds may be required.
Responsibilities
  • Manage employee engagement initiatives at the Coral Springs site, including employee connection, communication forums, feedback mechanisms, and organization development initiatives.
  • Support organization-culture initiatives, engagement surveys, exit interviews, feedback, action planning, and execution in collaboration with department heads and functional managers.
  • Support the end-to-end employee reward and recognition process, including managing the reward-and-recognition platform, creating awareness, driving participation, and administering quarterly and annual recognition.
  • Support the orientation and onboarding process to provide new hires with a seamless transition into the organization.
  • Support Good Manufacturing Practice compliance-related activities and maintain employee job descriptions, organizational charts, and other data within the scope of regulatory compliance.
  • Participate in developing new policies, procedures, and programs.
  • Compile and prepare data for statistical reporting.
  • Support employee-relations initiatives, address employee grievances, conduct employee interviews, support progressive-discipline policies, and foster constructive employee relations at the site.
  • Update and maintain human resources information management systems, conduct timely audits and reporting, ensure payroll-input accuracy, and support timely rollout and execution of the performance-management process.
  • Perform data analytics and management information systems work and provide insights on retention, exit surveys, employee cost, and budgeting.
  • Assist the Human Resources team with future projects and other responsibilities assigned by management.
Desired Qualifications
  • Previous experience working in a pharmaceutical or life sciences company is an added advantage.

About the company

Lupin Limited develops and sells branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients across over 100 markets. It brings medicines to patients by designing formulations and APIs, manufacturing at 15 sites, and distributing through a global network, supported by 7 research centers. Its integrated model combines a broad product portfolio with dedicated manufacturing, diagnostics, digital health, and manufacturing services to serve multiple therapeutic areas. Its goal is to improve patient health outcomes by expanding access to high-quality medicines and strengthening its global research, manufacturing, and digital capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Mumbai, India

Founded

1968

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 FY2027 sales rose 33.3% to INR 82,172 million on August 6, 2026.
  • September 4, 2026 FDA approval for modafinil widens Lupin’s U.S. CNS portfolio.
  • August 20, 2026 YUVEZZI deal opens Europe, UK, Switzerland, Norway, and Iceland.

What critics are saying

  • Management warned August 2026 of U.S. revenue moderation from tolvaptan and mirabegron competition.
  • Pithampur Unit II still carries OAI status, keeping FDA remediation pressure alive into 2027.
  • A serious U.S. manufacturing shutdown at Somerset or Pithampur would freeze launches and margins.

What makes Lupin Pharmaceuticals unique

  • Lupin combines first-to-file generics, biosimilars, and specialty ophthalmology after VISUfarma’s 2026 acquisition.
  • Ranluspec became June 2026’s only interchangeable ranibizumab biosimilar in vials and syringes.
  • FY2026 filings reached 430 ANDAs, signaling a durable U.S. scale machine.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

14%

1 year growth

15%

2 year growth

15%
PR Newswire
Aug 20th, 2026
Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

PR Newswire
Aug 17th, 2026
Lupin receives US FDA approval for generic Pitolisant tablets

Lupin Limited has received final approval from the US Food and Drug Administration for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The FDA approved Lupin's tablets as bioequivalent to Wakix for the indications in the approved labelling. Lupin is a Mumbai-based global pharmaceutical company that distributes products in over 100 markets. The company specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and six research centres globally, employing over 26,000 professionals.

PR Newswire
Jul 30th, 2026
Lupin launches generic Sugammadex injection in US after FDA approval

Lupin Limited has received US FDA approval and launched Sugammadex Injection in the United States. The product is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex Injection is bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery. Lupin is a Mumbai-based pharmaceutical company with products distributed in over 100 markets. The firm specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centres globally, employing over 26,000 professionals.

Multibagg AI
Jul 2nd, 2026
Lupin subsidiary to acquire 43.38% stake in Philippines' MPPI for up to $39.6M by May 2026

Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

PR Newswire
Jun 26th, 2026
Lupin receives tentative US FDA approval for generic Enzalutamide tablets

Lupin Limited has received tentative approval from the US FDA for its Enzalutamide Tablets in 40mg, 80mg, 120mg and 160mg strengths. The 40mg and 80mg versions were approved as bioequivalent to Astellas' Xtandi Tablets. Whilst Xtandi traditionally comes in 40mg and 80mg strengths, Lupin's tentatively approved 120mg and 160mg formulations will offer healthcare providers and patients additional dosing options. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally. Lupin operates 15 manufacturing sites and seven research centres worldwide, employing over 24,000 professionals. The company specialises in branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments.